Dimension Therapeutics Inc. (NASDAQ:DMTX) shot up 5.5% during trading on Monday . The company traded as high as $9.98 and last traded at $9.81, with a volume of 173,280 shares trading hands. The stock had previously closed at $9.30.

A number of research firms recently commented on DMTX. Zacks Investment Research raised Dimension Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 24th. Cantor Fitzgerald reissued a “buy” rating on shares of Dimension Therapeutics in a research report on Wednesday, June 22nd. Chardan Capital set a $10.00 price target on Dimension Therapeutics and gave the company a “hold” rating in a research report on Sunday, August 21st. Jefferies Group began coverage on Dimension Therapeutics in a research report on Thursday, June 2nd. They issued a “buy” rating and a $12.00 price target for the company. Finally, Canaccord Genuity set a $20.00 price target on Dimension Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 11th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Dimension Therapeutics presently has an average rating of “Buy” and an average target price of $17.19.

The firm’s market capitalization is $238.78 million. The stock’s 50 day moving average is $6.82 and its 200 day moving average is $7.36.

Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative net margin of 459.47% and a negative return on equity of 66.58%. On average, equities research analysts predict that Dimension Therapeutics Inc. will post ($1.91) earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in DMTX. FIL Ltd purchased a new stake in Dimension Therapeutics during the second quarter valued at $10,133,000. Vanguard Group Inc. raised its stake in Dimension Therapeutics by 447.4% in the second quarter. Vanguard Group Inc. now owns 426,165 shares of the company’s stock valued at $2,557,000 after buying an additional 348,311 shares in the last quarter. BlackRock Fund Advisors raised its stake in Dimension Therapeutics by 119.2% in the second quarter. BlackRock Fund Advisors now owns 317,232 shares of the company’s stock valued at $1,903,000 after buying an additional 172,495 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Dimension Therapeutics by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 239,000 shares of the company’s stock valued at $1,871,000 after buying an additional 80,200 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new stake in Dimension Therapeutics during the second quarter valued at $367,000. Institutional investors own 85.80% of the company’s stock.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.